Divider_Raft_Oars_B 1 Mobile_Page Divider_Dock 2 (1)

Twice-Daily Dosing Treats Acromegaly All Day, Every Day1

Make Your Move: Reach Maintenance in Under 2 Months1
MYCAPSSA may be initiated as soon as the patient shows a response and is able to tolerate treatment with octreotide or lanreotide.1
Example of treatment schedule:
Arrow Syringe Desktop Arrow Syringe Mobile
IGF-I, insulin-like growth factor; iSSA, injectable somatostatin analog.
*In patients who respond to and tolerate treatment with iSSA.
Based on the evaluation of IGF-I, signs, and symptoms.
Once the maintenance dosage is achieved, monitor IGF-I, signs, and symptoms periodically.
Rapid and Personalized Titration With MYCAPSSA
Evaluate IGF-I, signs, and symptoms every 2 weeks during the dose titration period. Adjust dose if needed.1
Example of titration schedule1:
Titration desktop 1
Titration mobile 1
In the OPTIMAL trial: The majority of MYCAPSSA-treated patients titrated to the 80-mg dose.1 Adverse events were not dose related.2
Treat Acromegaly and Its Symptoms All Day, Every Day1
MYCAPSSA offers a flexible dosing schedule.
  • First and second doses do not need to be taken exactly 12 hours apart or at the same time each day
  • MYCAPSSA should be taken 1 hour before or 2 hours after meals
mycapssa_capsule CHI_mycapssa_package_CS_300_Silo 2
Each wallet of MYCAPSSA comes with 28 capsules. Each MYCAPSSA capsule is 20 mg.
Not Refridgerated
Once opened, MYCAPSSA wallets can be stored at room temperature for 30 days, and do not need to be refrigerated.*
Opened wallets may be stored at room temperature (68° to 77°F) for up to 1 month.
“I love to travel and just take that wallet of pills, 
throw it in my suitcase and go on with life.”

— Becky, MYCAPSSA patient

This is Becky's experience and may not be representative of every patient taking MYCAPSSA.
Becky-Broll-2
Let’s Connect
Get in touch with a MYCAPSSA Sales Representative.
REQUEST A REP

Important Safety Information

Contraindications

Hypersensitivity to octreotide or any of the components of MYCAPSSA. Anaphylactoid reactions, including anaphylactic shock, have been reported in patients receiving octreotide.


Warnings and Precautions

MYCAPSSA can cause problems with the gallbladder. Monitor patients periodically. Discontinue if complications of cholelithiasis are suspected.

Blood sugar, thyroid levels, and vitamin B12 levels should be monitored and treated accordingly.

Bradycardia, arrhythmia, or conduction abnormalities may occur. Treatment with drugs that have bradycardia effects may need to be adjusted.

New onset of steatorrhea, stool discoloration, loose stools, abdominal bloating, and weight loss may occur with MYCAPSSA and other somatostatin analogs. If new occurrence or worsening of these symptoms are reported, evaluate for potential pancreatic exocrine insufficiency and manage accordingly.


Adverse Reactions

The most common adverse reactions (incidence >10%) are nausea, diarrhea, headache, arthralgia, asthenia, hyperhidrosis, peripheral swelling, blood glucose increased, vomiting, abdominal discomfort, dyspepsia, sinusitis, and osteoarthritis.


Drug Interactions

The following drugs require monitoring and possible dose adjustment when used with MYCAPSSA: cyclosporine, insulin, antidiabetic drugs, calcium channel blockers, beta blockers, lisinopril, digoxin, bromocriptine, and drugs mainly metabolized by CYP3A4. Counsel women taking an oral contraceptive to use an alternative non-hormonal method of contraception or a back-up method when taking MYCAPSSA.

Patients taking proton pump inhibitors, H2-receptor antagonists, or antacids concomitantly with MYCAPSSA may require increased dosages of MYCAPSSA.


Pregnancy

Advise premenopausal females of the potential for an unintended pregnancy.

Please report adverse events to Chiesi Farmaceutici S.p.A. at 1-888-661-9260 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see Full Prescribing Information, including Medication Guide.

Indication

Indication and usage

MYCAPSSA (octreotide) delayed-release capsules, for oral use, is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.

Important Safety Information

Contraindications

Hypersensitivity to octreotide or any of the components of MYCAPSSA. Anaphylactoid reactions, including anaphylactic shock, have been reported in patients receiving octreotide.


Warnings and Precautions

MYCAPSSA can cause problems with the gallbladder. Monitor patients periodically. Discontinue if complications of cholelithiasis are suspected.

Blood sugar, thyroid levels, and vitamin B12 levels should be monitored and treated accordingly.

Bradycardia, arrhythmia, or conduction abnormalities may occur. Treatment with drugs that have bradycardia effects may need to be adjusted.

New onset of steatorrhea, stool discoloration, loose stools, abdominal bloating, and weight loss may occur with MYCAPSSA and other somatostatin analogs. If new occurrence or worsening of these symptoms are reported, evaluate for potential pancreatic exocrine insufficiency and manage accordingly.


Adverse Reactions

The most common adverse reactions (incidence >10%) are nausea, diarrhea, headache, arthralgia, asthenia, hyperhidrosis, peripheral swelling, blood glucose increased, vomiting, abdominal discomfort, dyspepsia, sinusitis, and osteoarthritis.


Drug Interactions

The following drugs require monitoring and possible dose adjustment when used with MYCAPSSA: cyclosporine, insulin, antidiabetic drugs, calcium channel blockers, beta blockers, lisinopril, digoxin, bromocriptine, and drugs mainly metabolized by CYP3A4. Counsel women taking an oral contraceptive to use an alternative non-hormonal method of contraception or a back-up method when taking MYCAPSSA.

Patients taking proton pump inhibitors, H2-receptor antagonists, or antacids concomitantly with MYCAPSSA may require increased dosages of MYCAPSSA.


Pregnancy

Advise premenopausal females of the potential for an unintended pregnancy.

Please report adverse events to Chiesi Farmaceutici S.p.A. at 1-888-661-9260 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see Full Prescribing Information, including Medication Guide.

Indication

Indication and usage

MYCAPSSA (octreotide) delayed-release capsules, for oral use, is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.


REFERENCES: 1. MYCAPSSA [package insert]. Chiesi USA, Inc. 2024. 2. Melmed S, et al. J Clin Endocrinol Metab. 2015;100(4):1699-1708.